SCHEMBL6837557

SCHEMBL6837557

CN(C)CCOc1ccc(CC(=O)NO)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 5/20 0.70
KDM4E B2RXH2 1/20 0.70
CYP1A2 P05177 1/20 0.70
CYP2D6 P10635 1/20 0.70
PDE4A P27815 1/20 0.70
SMN1; SMN2 Q16637 1/20 0.70
HIF1A Q16665 1/20 0.70
HDAC10 Q969S8 1/20 0.70
HRH3 Q9Y5N1 3/20 0.57
LTA4H P09960 1/20 0.56
KEAP1 Q14145 1/20 0.55
NFE2L2 Q16236 1/20 0.55
ESR1 P03372 4/20 0.54
HDAC3 O15379 3/20 0.54
NCOR2 Q9Y618 3/20 0.54
ALDH1A1 P00352 2/20 0.54
GAA P10253 1/20 0.54
LMNA P02545 1/20 0.49
HDAC1 Q13547 1/20 0.49
DRD2 P14416 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15522665 0.88 HDAC6 (0.66) HDAC6KDM4ECYP1A2CYP2D6PDE4A
SCHEMBL18294051 0.87 KEAP1 (0.58) HDAC6KDM4ECYP1A2CYP2D6PDE4A
SCHEMBL12315757 0.83 ALDH1A1 (0.67) KDM4ECYP1A2SMN1; SMN2HRH3LTA4H
SCHEMBL7150669 0.83 HRH3 (0.62) KDM4ECYP1A2SMN1; SMN2HRH3LTA4H
SCHEMBL2777642 0.83 CYP1A2 (0.88) HDAC6KDM4ECYP1A2CYP2D6PDE4A
SCHEMBL25377781 0.83 HRH3 (0.62) KDM4ESMN1; SMN2HRH3LTA4HKEAP1
Bufexamac SCHEMBL25215 0.83 KDM4E (1.00) HDAC6KDM4ECYP1A2CYP2D6PDE4A
Bufexamac SCHEMBL5076113 0.83 KDM4E (1.00) HDAC6KDM4ECYP1A2CYP2D6PDE4A
Bufexamac SCHEMBL15456779 0.81 KDM4E (0.97) HDAC6KDM4ECYP1A2CYP2D6PDE4A
SCHEMBL17890405 0.81 HRH3 (0.60) KDM4ECYP1A2SMN1; SMN2HRH3LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030008849-A1 Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors LEVIN JEREMY I (US) 2003-01-09 US claimed
US-20040033988-A1 Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors WYETH (US) 2004-02-19 US disclosed
US-20030008849-A1 Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors LEVIN JEREMY I (US) 2003-01-09 US disclosed
EP-1144368-A2 ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS American Cyanamid Company (US) 2001-10-17 EP disclosed
WO-2000044709-A2 ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008849-A1 Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors TNF, SI, TASP1 HDAC6 163/4885KDM4E 3928/4885CYP1A2 2814/4885
US-20040033988-A1 Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors TNF, SI, TASP1 HDAC6 163/4885KDM4E 3928/4885CYP1A2 2814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.